2024 Publications
Allegretti JR, Brady JH, Wicker A, Latymer M, Wells A. Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review. Adv Ther. 2024 May;41(5):1775-1794. doi: 10.1007/s12325-024-02818-9. Epub 2024 Mar 11. PMID: 38466559; PMCID: PMC11052875.
Allegretti JR, Axelrad J, Dalal RS, Kelly CR, Grinspan A, Fischer M. Outcomes after Fecal Microbiota Transplantation in combination with Bezlotoxumab for Inflammatory Bowel Disease and Recurrent C . difficile Infection. Am J Gastroenterol. 2024 Mar 19. doi: 10.14309/ajg.0000000000002770. Epub ahead of print. PMID: 38501667.
Kratchmarov R, Djeddi S, Dunlap G, He W, Jia X, Burk CM, Ryan T, McGill A, Allegretti JR, Kataru RP, Mehrara BJ, Taylor EM, Agarwal S, Bhattacharyya N, Bergmark RW, Maxfield AZ, Lee S, Roditi R, Dwyer DF, Boyce JA, Buchheit KM, Laidlaw TM, Shreffler WG, Rao DA, Gutierrez-Arcelus M, Brennan PJ. TCF1-LEF1 co-expression identifies a multipotent progenitor cell (TH2-MPP) across human allergic diseases. Nat Immunol. 2024 May;25(5):902-915. doi: 10.1038/s41590-024-01803-2. Epub 2024 Apr 8. PMID: 38589618.
Clarke LM, Allegretti JR. The epidemiology and management of Clostridioides difficile infection-A clinical update. Aliment Pharmacol Ther. 2024 Mar 27. doi: 10.1111/apt.17975. Epub ahead of print. PMID: 38534216.
Dalal RS, Kallumkal G, Cabral HJ, Barnes EL, Allegretti JR. One-Year Comparative Effectiveness of Upadacitinib vs Tofacitinib for Ulcerative Colitis: A Multicenter Cohort Study. Am J Gastroenterol. 2024 Apr 1. doi: 10.14309/ajg.0000000000002746. Epub ahead of print. PMID: 38470031.
Dalal RS, Winter RW, Gupta S, Sasson GF, Hamilton MJ, Allegretti JR. Clinical Outcomes at 8-16 Weeks After Upadacitinib Initiation for Acute Severe Ulcerative Colitis: A Case Series in the United States. Inflamm Bowel Dis. 2024 Feb 26:izae038. doi: 10.1093/ibd/izae038. Epub ahead of print. PMID: 38408096.
Feuerstadt P, Allegretti JR, Dubberke ER, Guo A, Harvey A, Yang M, Garcia-Horton V, Fillbrunn M, Tillotson G, Bancke LL, LaPlante K, Garey KW, Khanna S. Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infect Dis Ther. 2024 Jan;13(1):221-236. doi: 10.1007/s40121-023-00907-w. Epub 2024 Jan 18. PMID: 38236515.
Newman KL, Allegretti JR. Emerging Noninfectious Indications for Live Biotherapeutic Products in Gastroenterology. Am J Gastroenterol. 2024 Jan 1;119(1S):S30-S35. doi: 10.14309/ajg.0000000000002584. PMID: 38153224.
2023 Publications
Kelly CR, Allegretti JR. Review Article: Gastroenterology and Clostridium difficile Infection: Past, Present, and Future. Clin Infect Dis. 2023 Dec 5;77(Supplement_6):S463-S470. doi: 10.1093/cid/ciad644. PMID: 38051967.
Allegretti JR, Gecse KB, Chiorean MV, Argollo M, Guo X, Lawendy N, Su C, Mundayat R, Paulissen J, Salese L, Irving PM. Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain. J Gastroenterol Hepatol. 2023 Nov 12. doi: 10.1111/jgh.16386. Epub ahead of print. PMID: 37953548.
Dalal RS, Sharma PP, Bains K, Pruce JC, Allegretti JR. Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort. Inflamm Bowel Dis. 2023 Oct 16:izad242. doi: 10.1093/ibd/izad242. Epub ahead of print. PMID: 37843044.
Dalal RS, Nørgård BM, Zegers FD, Kjeldsen J, Friedman S, Allegretti JR, Lund K. Older Adult-Onset of Inflammatory Bowel Diseases Is Associated With Higher Utilization of Analgesics: A Nationwide Cohort Study. Am J Gastroenterol. 2023 Oct 2. doi: 10.14309/ajg.0000000000002497. Epub ahead of print. PMID: 37713526.
Dalal RS, Kallumkal G, Cabral HJ, Bachour S, Barnes EL, Allegretti JR. Comparative Effectiveness of Upadacitinib vs Ustekinumab for Ulcerative Colitis: A Multicenter Retrospective Cohort Study. Clin Gastroenterol Hepatol. 2023 Sep 5:S1542-3565(23)00671-7. doi: 10.1016/j.cgh.2023.08.021. Epub ahead of print. PMID: 37673349.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, et al. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Gastroenterology. 2023 Aug 31:S0016-5085(23)04963-6. doi: 10.1053/j.gastro.2023.08.038. Epub ahead of print. PMID: 37659673.
Dalal RS, Sharma PP, Bains K, Pruce JC, Allegretti JR. 1-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib vs Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States. Inflamm Bowel Dis. 2023 Aug 24:izad165. doi: 10.1093/ibd/izad165. Epub ahead of print. PMID: 37619234.
Allegretti JR, Khanna S, Feuerstadt P. Practical Use of VOWST (fecal microbiota live spores - bprk) for the Prevention of Recurrent Clostridioides difficile Infection. Am J Gastroenterol. 2023 Aug 10. doi: 10.14309/ajg.0000000000002463. Epub ahead of print. PMID: 37566894.
Kanjee Z, Allegretti JR, Alonso CD, Burns RB. How Would You Manage This Patient With Clostridioides difficile Infection? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med. 2023 Aug;176(8):1101-1108. doi: 10.7326/M23-0754. Epub 2023 Aug 8. PMID: 37549387.
Dalal RS, Lund K, Zegers FD, Friedman S, Allegretti JR, Nørgård BM. Use of Tramadol vs Traditional Opioids and Adverse Outcomes in Patients with Inflammatory Bowel Disease: A Danish Nationwide Cohort Study. Inflamm Bowel Dis. 2023 Jul 31:izad156. doi: 10.1093/ibd/izad156. Epub ahead of print. PMID: 37523667.
Dalal RS, Kallumkal G, Cabral HJ, Bachour S, Barnes EL, Allegretti JR. Clinical and Endoscopic Outcomes After Upadacitinib Induction for Ulcerative Colitis: A Multicenter Retrospective Cohort Study. Inflamm Bowel Dis. 2023 Jul 27:izad155. doi: 10.1093/ibd/izad155. Epub ahead of print. PMID: 37498971.
Dalal RS, Ermann J, Carlin A, Mitri J, Allegretti JR. Activity of axial spondyloarthritis after one year of anti-tumor necrosis factor therapy among patients with inflammatory bowel diseases. Clin Rheumatol. 2023 Jul 10. doi: 10.1007/s10067-023-06695-5. Epub ahead of print. PMID: 37428414.
Dalal RS, Sharma PP, Bains K, Pruce JC, Allegretti JR. 1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure. Inflamm Bowel Dis. 2023 May 20:izad087. doi: 10.1093/ibd/izad087. Epub ahead of print. PMID: 37209416.
Bachour SP, Dalal R, Allegretti JR. The impact of the COVID-19 pandemic on Clostridioides difficile infection and utilization of fecal microbiota transplantation. Therap Adv Gastroenterol. 2023 Apr 17;16:17562848231165581. doi: 10.1177/17562848231165581. PMID: 37091531; PMCID: PMC10107020.
Allegretti JR, Mitsialis V, Canavan JB; Low-Dose IL2 UC Study Group; Snapper SB. Low-Dose Interleukin 2 for the Treatment of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2023 Apr 7:S0016-5085(23)00584-X. doi: 10.1053/j.gastro.2023.03.230. Epub ahead of print. PMID: 37030335.
Kralicek SE, Jenkins C, Allegretti JR, Lewis JD, Osman M, Hecht GA. Transmission of the Potential Pathogen Atypical Enteropathogenic Escherichia coli by Fecal Microbiota Transplant. Gastroenterology. 2023 Mar 28:S0016-5085(23)00536-X. doi: 10.1053/j.gastro.2023.03.222. Epub ahead of print. PMID: 36990294.
Lee SD, Allegretti JR, Steinwurz F, Connelly SB, Lawendy N, Paulissen J, Gecse KB. Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore. BMC Gastroenterol. 2023 Feb 8;23(1):34. doi: 10.1186/s12876-022-02508-2. PMID: 36755231; PMCID: PMC9906955.
Feuerstadt P, Allegretti JR, Khanna S. Practical Use of Rebyota for the Prevention of Recurrent Clostridioides difficile Infection. Am J Gastroenterol. 2023 Jan 25. doi: 10.14309/ajg.0000000000002195. Epub ahead of print. PMID: 36695753.
Bustamante JM, Dawson T, Loeffler C, Marfori Z, Marchesi JR, Mullish BH, Thompson CC, Crandall KA, Rahnavard A, Allegretti JR, Cummings BP. Impact of Fecal Microbiota Transplantation on Gut Bacterial Bile Acid Metabolism in Humans. Nutrients. 2022 Dec 7;14(24):5200. doi: 10.3390/nu14245200. PMID: 36558359; PMCID: PMC9785599.
2022 Publications
Hudesman DP, Torres J, Salese L, Woolcott JC, Mundayat R, Su C, Mosli MH, Allegretti JR. Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program. Patient. 2022 Nov 7. doi: 10.1007/s40271-022-00603-w. Epub ahead of print. PMID: 36336750.
Mullish BH, Martinez-Gili L, Chekmeneva E, Correia GDS, Lewis MR, Horneffer-Van Der Sluis V, Roberts LA, McDonald JAK, Pechlivanis A, Walters JRF, McClure EL, Marchesi JR, Allegretti JR. Assessing the clinical value of faecal bile acid profiling to predict recurrence in primary Clostridioides difficile infection. Aliment Pharmacol Ther. 2022 Oct 17. doi: 10.1111/apt.17247. Epub ahead of print. PMID: 36250604.
Dalal RS, Mitri J, Goodrick H, Allegretti JR. Risk of Gastrointestinal Infections After Initiating Vedolizumab and Anti-TNFα Agents for Ulcerative Colitis. J Clin Gastroenterol. 2022 Aug 4. doi: 10.1097/MCG.0000000000001733. Epub ahead of print. PMID: 36156528.
Allegretti JR. Should faecal microbiota transplantation be used earlier in the treatment framework? Lancet Gastroenterol Hepatol. 2022 Sep 21:S2468-1253(22)00301-6. doi: 10.1016/S2468-1253(22)00301-6. Epub ahead of print. PMID: 36152634.
Vaughn BP, Fischer M, Kelly CR, Allegretti JR, Graiziger C, Thomas J, McClure E, Kabage AJ, Khoruts A. Effectiveness and safety of colonic and capsule fecal microbiota transplantation for recurrent Clostridioides difficile infection. Clin Gastroenterol Hepatol. 2022 Sep 17:S1542-3565(22)00880-1. doi: 10.1016/j.cgh.2022.09.008. Epub ahead of print. PMID: 36126907.
Montano-Loza AJ, Allegretti JR, Cheung A, Ebadi M, Jones D, Kerkar N, Levy C, Rizvi S, Vierling JM, Alvarez F, Bai W, Gilmour S, Gulamhusein A, Guttman O, Hansen BE, MacParland S, Mason A, Onofrio F, Santamaria P, Stueck A, Swain M, Vincent C, Ricciuto A, Hirschfield G. Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver. Can Liver J. 2021 Nov 11;4(4):401-425. doi: 10.3138/canlivj-2021-0006. PMID: 35989897; PMCID: PMC9235119.
Dalal RS, Pruce JC, Allegretti JR. Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2022 Jul 30:izac164. doi: 10.1093/ibd/izac164. Epub ahead of print. PMID: 35907202.
Shore BM, Weaver KN, Allegretti JR, Herfarth HH, Barnes EL. Prevalence of Clostridioides difficile Infection After Ileal Pouch-anal Anastomosis in Patients With Chronic Antibiotic-dependent Pouchitis and Crohn's-like Disease of the Pouch. Inflamm Bowel Dis. 2022 Jul 29:izac165. doi: 10.1093/ibd/izac165. Epub ahead of print. PMID: 35905034.
Dalal RS, Bains K, Marcus J, McClure EL, Allegretti JR. Tofacitinib for the Treatment of Pouch-Related Disorders: A Case Series. Inflamm Bowel Dis. 2022 Jul 6:izac147. doi: 10.1093/ibd/izac147. Epub ahead of print. PMID: 35792486.
Dawkins JJ, Allegretti JR, Gibson TE, McClure E, Delaney M, Bry L, Gerber GK. Gut metabolites predict Clostridioides difficile recurrence. Microbiome. 2022 Jun 9;10(1):87. doi: 10.1186/s40168-022-01284-1. PMID: 35681218; PMCID: PMC9178838.
Gupta S, Allegretti JR. Mimics of Crohn's Disease. Gastroenterol Clin North Am. 2022 Jun;51(2):241-269. doi: 10.1016/j.gtc.2021.12.006. Epub 2022 Apr 27. PMID: 35595413.
Dalal RS, McClure EL, Marcus J, Allegretti JR. Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naïve Patients with Ulcerative Colitis. Dig Dis Sci. 2022 Apr 12. doi: 10.1007/s10620-022-07472-1. Epub ahead of print. PMID: 35415826.
Osman M, Budree S, Kelly CR, Panchal P, Allegretti JR, Kassam Z; OPENBIOME COLLABORATORS, Olesen SW, Ramakrishna B, Dubois N, O'Brien K, Fischer M, Stollman N, Hays RA, Kelly CP, Amaratunga K, Crothers JW, Abend A, Bougas M, Burns L, Decaille-Hodge I, Dickens M, Edelstein C, Gabdrakhmanova D, Landry R, Ling K, Martin D, Medina G, Mendolia G, Muñoz R, Rao S, Seng M, Stehler L, Yoder K, Zellmer C. Effectiveness and Safety of Fecal Microbiota Transplantation for Clostridioides Difficile Infection: Results From a 5344-Patient Cohort Study. Gastroenterology. 2022 Apr 7:S0016-5085(22)00351-1. doi: 10.1053/j.gastro.2022.03.051. Epub ahead of print. PMID: 35398345.
Chiorean MV, Allegretti JR, Sharma PP, Chastek B, Salese L, Bell EJ, Peterson-Brandt J, Cappelleri JC, Guo X, Khan N. Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis. BMC Gastroenterol. 2022 Apr 9;22(1):177. doi: 10.1186/s12876-022-02215-y. PMID: 35397501; PMCID: PMC8994921.
Hassan-Zahraee M, Ye Z, Xi L, Baniecki ML, Li X, Hyde CL, Zhang J, Raha N, Karlsson F, Quan J, Ziemek D, Neelakantan S, Lepsy C, Allegretti JR, Romatowski J, Scherl EJ, Klopocka M, Danese S, Chandra DE, Schoenbeck U, Vincent MS, Longman R, Hung KE. Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis. Inflamm Bowel Dis. 2022 Mar 2;28(3):434-446. doi: 10.1093/ibd/izab193. PMID: 34427649; PMCID: PMC8889296.
Dalal RS, Gupta S, Goodrick H, Mitri J, Allegretti JR. Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders. Inflamm Bowel Dis. 2022 Jan 5;28(1):146-149. doi: 10.1093/ibd/izab156. PMID: 34245267; PMCID: PMC8730681.
2021 Publications
Allegretti JR, Canakis A, McClure E, Marcus J, Norton BA, Hamilton MJ, Winter RW, De Silva PS, Friedman S, Korzenik JR. Infliximab De-escalation in Patients With Crohn's Disease in Clinical Remission Is Safe and Well-tolerated. Inflamm Bowel Dis. 2021 Nov 15;27(12):2031-2033. doi: 10.1093/ibd/izab131. PMID: 34142700.
Danese S, Klopocka M, Scherl EJ, Romatowski J, Allegretti JR, Peeva E, Vincent MS, Schoenbeck U, Ye Z, Hassan-Zahraee M, Rath N, Li G, Neelakantan S, Banfield C, Lepsy C, Chandra DE, Hung KE. Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. Clin Gastroenterol Hepatol. 2021 Nov;19(11):2324-2332.e6. doi: 10.1016/j.cgh.2021.06.011. Epub 2021 Jun 12. PMID: 34126262.
Mullish BH, Allegretti JR. The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection. Therap Adv Gastroenterol. 2021 May 28;14:17562848211017725. doi: 10.1177/17562848211017725. PMID: 34104212; PMCID: PMC8165815.
Allegretti JR. Update on Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2021 Jan;17(1):31-34. PMID: 34035760; PMCID: PMC8132680.
Allegretti JR, Nije C, McClure E, Redd WD, Wong D, Zhou JC, Bazarbashi AN, McCarty TR, Hathorn KE, Shen L, Jajoo K, Chan WW. Prevalence and impact of Clostridioides difficile infection among hospitalized patients with coranavirus disease 2019. JGH Open. 2021 Mar 30;5(5):622-625. doi: 10.1002/jgh3.12497. PMID: 34013064; PMCID: PMC8114993.
Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol. 2021 Jun 1;116(6):1124-1147. doi: 10.14309/ajg.0000000000001278. Erratum in: Am J Gastroenterol. 2022 Feb 1;117(2):358. PMID: 34003176.
Dalal RS, Mitri J, Goodrick H, Allegretti JR. Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis. Inflamm Bowel Dis. 2021 Oct 18;27(10):1694-1697. doi: 10.1093/ibd/izab097. PMID: 33988235; PMCID: PMC8522788.
Gupta S, Mullish BH, Allegretti JR. Fecal Microbiota Transplantation: The Evolving Risk Landscape. Am J Gastroenterol. 2021 Apr;116(4):647-656. doi: 10.14309/ajg.0000000000001075. PMID: 33982930.
Dalal RS, Esckilsen S, Barnes EL, Pruce JC, Marcus J, Allegretti JR. Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2021 Mar 26:S1542-3565(21)00338-4. doi: 10.1016/j.cgh.2021.03.028. Epub ahead of print. PMID: 33775893; PMCID: PMC8464615.
Gupta S, Zhu J, McCarty TR, Pruce J, Kassam Z, Kelly C, Fischer M, Allegretti JR. Cost-effectiveness analysis of sequential fecal microbiota transplantation for fulminant Clostridioides difficile infection. J Gastroenterol Hepatol. 2021 Sep;36(9):2432-2440. doi: 10.1111/jgh.15483. Epub 2021 Mar 17. PMID: 33682170.
Dalal RS, Allegretti JR. Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease. Curr Opin Gastroenterol. 2021 Jul 1;37(4):336-343. doi: 10.1097/MOG.0000000000000739. PMID: 33654015; PMCID: PMC8169557.
Fujimoto K, Kimura Y, Allegretti JR, Yamamoto M, Zhang YZ, Katayama K, Tremmel G, Kawaguchi Y, Shimohigoshi M, Hayashi T, Uematsu M, Yamaguchi K, Furukawa Y, Akiyama Y, Yamaguchi R, Crowe SE, Ernst PB, Miyano S, Kiyono H, Imoto S, Uematsu S. Functional Restoration of Bacteriomes and Viromes by Fecal Microbiota Transplantation. Gastroenterology. 2021 May;160(6):2089-2102.e12. doi: 10.1053/j.gastro.2021.02.013. Epub 2021 Feb 9. PMID: 33577875; PMCID: PMC8684800.
Ianiro G, Mullish BH, Hvas CL, Segal JP, Kuijper EJ, Costello SP, Kelly CR, Allegretti JR, Fischer M, Iqbal TH, Satokari R, Kao D, van Prehn J, Ng SC, Bibbò S, Baunwall SMD, Quraishi MN, Sokol H, Zhang F, Keller J, Masucci L, Quaranta G, Kassam Z, Sanguinetti M, Tilg H, Gasbarrini A, Cammarota G. SARS-CoV-2 vaccines and donor recruitment for FMT. Lancet Gastroenterol Hepatol. 2021 Apr;6(4):264-266. doi: 10.1016/S2468-1253(21)00032-7. Epub 2021 Feb 8. PMID: 33571456; PMCID: PMC7906701.
Dalal RS, Allegretti JR. Ustekinumab Dose Optimization in Crohn Disease: One Size Does Not Fit All. Inflamm Bowel Dis. 2021 May 17;27(6):e70. doi: 10.1093/ibd/izab019. PMID: 33570151; PMCID: PMC8128381.
Winter RW, Ananthakrishnan A, Burke KE, Kochar B, Chan WW, Allegretti JR. Time to Negative SARS-CoV-2 PCR Should Not Delay Care Among Patients With Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2021 Mar 15;27(4):590-592. doi: 10.1093/ibd/izab023. PMID: 33570095; PMCID: PMC7928903.
Dalal RS, McClure E, Marcus J, Winter RW, Hamilton MJ, Allegretti JR. COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 Aug;19(8):1730-1732.e2. doi: 10.1016/j.cgh.2021.02.004. Epub 2021 Feb 4. PMID: 33549869; PMCID: PMC7859624.
Dalal RS, Allegretti JR. Fecal Microbiota Transplantation for Chronic Pouchitis: Promising Novel Therapeutic or Lost Cause? Inflamm Bowel Dis. 2021 Oct 20;27(11):1873-1875. doi: 10.1093/ibd/izab002. PMID: 33501941; PMCID: PMC8528143.
Allegretti JR, Kassam Z, Hurtado J, Marchesi JR, Mullish BH, Chiang A, Thompson CC, Cummings BP. Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity. Hormones (Athens). 2021 Mar;20(1):209-211. doi: 10.1007/s42000-020-00265-z. Epub 2021 Jan 9. PMID: 33420959; PMCID: PMC8432937.
Gerardin Y, Timberlake S, Allegretti JR, Smith MB, Kassam Z. Beyond Fecal Microbiota Transplantation: Developing Drugs from the Microbiome. J Infect Dis. 2021 Jun 16;223(12 Suppl 2):S276-S282. doi: 10.1093/infdis/jiaa700. PMID: 33330910.
Allegretti JR, Kelly CR, Grinspan A, Mullish BH, Hurtado J, Carrellas M, Marcus J, Marchesi JR, McDonald JAK, Gerardin Y, Silverstein M, Pechlivanis A, Barker GF, Miguens Blanco J, Alexander JL, Gallagher KI, Pettee W, Phelps E, Nemes S, Sagi SV, Bohm M, Kassam Z, Fischer M. Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection. Inflamm Bowel Dis. 2021 Aug 19;27(9):1371-1378. doi: 10.1093/ibd/izaa283. PMID: 33155639; PMCID: PMC8376126.
Dalal RS, Njie C, Marcus J, Gupta S, Allegretti JR. Predictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification. Inflamm Bowel Dis. 2021 Jul 27;27(8):1294-1301. doi: 10.1093/ibd/izaa282. PMID: 33146703; PMCID: PMC8314105.
Burke KE, Kochar B, Allegretti JR, Winter RW, Lochhead P, Khalili H, Colizzo FP, Hamilton MJ, Chan WW, Ananthakrishnan AN. Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2021 Jan 19;27(2):155-161. doi: 10.1093/ibd/izaa278. PMID: 33089863; PMCID: PMC7665507.
Kelly CR, Yen EF, Grinspan AM, Kahn SA, Atreja A, Lewis JD, Moore TA, Rubin DT, Kim AM, Serra S, Nersesova Y, Fredell L, Hunsicker D, McDonald D, Knight R, Allegretti JR, Pekow J, Absah I, Hsu R, Vincent J, Khanna S, Tangen L, Crawford CV, Mattar MC, Chen LA, Fischer M, Arsenescu RI, Feuerstadt P, Goldstein J, Kerman D, Ehrlich AC, Wu GD, Laine L. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology. 2021 Jan;160(1):183-192.e3. doi: 10.1053/j.gastro.2020.09.038. Epub 2020 Oct 1. PMID: 33011173; PMCID: PMC8034505.
2020 Publications
Proença IM, Allegretti JR, Bernardo WM, de Moura DTH, Ponte Neto AM, Matsubayashi CO, Flor MM, Kotinda APST, de Moura EGH. Fecal microbiota transplantation improves metabolic syndrome parameters: systematic review with meta-analysis based on randomized clinical trials. Nutr Res. 2020 Nov;83:1-14. doi: 10.1016/j.nutres.2020.06.018. Epub 2020 Jul 3. PMID: 32987284.
Martinez-Gili L, McDonald JAK, Liu Z, Kao D, Allegretti JR, Monaghan TM, Barker GF, Miguéns Blanco J, Williams HRT, Holmes E, Thursz MR, Marchesi JR, Mullish BH. Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites. Gut Microbes. 2020 Nov 9;12(1):1810531. doi: 10.1080/19490976.2020.1810531. PMID: 32893721; PMCID: PMC7524310.
Allegretti JR, Kelly CR, Grinspan A, Mullish BH, Kassam Z, Fischer M. Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection. Gastroenterology. 2020 Nov;159(5):1982-1984. doi: 10.1053/j.gastro.2020.07.045. Epub 2020 Jul 30. PMID: 32738249.
Gupta S, Aihara H, Trivedi HD, Srivastava A, Allegretti JR, Hamilton MJ. Heading in the Right Dissection: Toward an Endoscopic Cancer Cure in a Patient with Long-Standing Ulcerative Colitis. Dig Dis Sci. 2020 Oct;65(10):2818-2822. doi: 10.1007/s10620-020-06465-2. PMID: 32661762.
Cheng YW, Alhaffar D, Saha S, Khanna S, Bohm M, Phelps E, Ghabril M, Orman E, Sashidhar S, Rogers N, Xu H, Khoruts A, Vaughn B, Kao D, Wong K, Cammarota G, Ianiro G, Dhere T, Kraft CS, Mehta N, Woodworth MH, Allegretti JR, Nativ L, Marcus J, El-Nachef N, Fischer M. Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis. Clin Gastroenterol Hepatol. 2021 Aug;19(8):1627-1634. doi: 10.1016/j.cgh.2020.06.051. Epub 2020 Jul 6. PMID: 32645451; PMCID: PMC8856132.
Ianiro G, Mullish BH, Kelly CR, Kassam Z, Kuijper EJ, Ng SC, Iqbal TH, Allegretti JR, Bibbò S, Sokol H, Zhang F, Fischer M, Costello SP, Keller JJ, Masucci L, van Prehn J, Quaranta G, Quraishi MN, Segal J, Kao D, Satokari R, Sanguinetti M, Tilg H, Gasbarrini A, Cammarota G. Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut. 2020 Sep;69(9):1555-1563. doi: 10.1136/gutjnl-2020-321829. Epub 2020 Jul 3. PMID: 32620549; PMCID: PMC7456726.
Allegretti JR, Elliott RJ, Ladha A, Njenga M, Warren K, O'Brien K, Budree S, Osman M, Fischer M, Kelly CR, Kassam Z. Stool processing speed and storage duration do not impact the clinical effectiveness of fecal microbiota transplantation. Gut Microbes. 2020 Nov 1;11(6):1806-1808. doi: 10.1080/19490976.2020.1768777. Epub 2020 Jun 18. PMID: 32552337; PMCID: PMC7524162.
Mitsialis V, Wall S, Liu P, Ordovas-Montanes J, Parmet T, Vukovic M, Spencer D, Field M, McCourt C, Toothaker J, Bousvaros A; Boston Children’s Hospital Inflammatory Bowel Disease Center; Brigham and Women’s Hospital Crohn’s and Colitis Center, Shalek AK, Kean L, Horwitz B, Goldsmith J, Tseng G, Snapper SB, Konnikova L. Single-Cell Analyses of Colon and Blood Reveal Distinct Immune Cell Signatures of Ulcerative Colitis and Crohn's Disease. Gastroenterology. 2020 Aug;159(2):591-608.e10. doi: 10.1053/j.gastro.2020.04.074. Epub 2020 May 16. PMID: 32428507; PMCID: PMC8166295.
Ianiro G, Mullish BH, Kelly CR, Sokol H, Kassam Z, Ng SC, Fischer M, Allegretti JR, Masucci L, Zhang F, Keller J, Sanguinetti M, Costello SP, Tilg H, Gasbarrini A, Cammarota G. Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. Lancet Gastroenterol Hepatol. 2020 May;5(5):430-432. doi: 10.1016/S2468-1253(20)30082-0. Epub 2020 Mar 17. Erratum in: Lancet Gastroenterol Hepatol. 2020 Jun;5(6):e5. PMID: 32192627; PMCID: PMC7104244.
Allegretti JR, Mehta SR, Kassam Z, Kelly CR, Kao D, Xu H, Fischer M. Risk Factors that Predict the Failure of Multiple Fecal Microbiota Transplantations for Clostridioides difficile Infection. Dig Dis Sci. 2021 Jan;66(1):213-217. doi: 10.1007/s10620-020-06198-2. Epub 2020 Mar 13. PMID: 32170474.
Lopetuso LR, Ianiro G, Allegretti JR, Bibbò S, Gasbarrini A, Scaldaferri F, Cammarota G. Fecal transplantation for ulcerative colitis: current evidence and future applications. Expert Opin Biol Ther. 2020 Apr;20(4):343-351. doi: 10.1080/14712598.2020.1733964. Epub 2020 Feb 26. PMID: 32083498.
Perler BK, Chen B, Phelps E, Allegretti JR, Fischer M, Ganapini V, Krajiceck E, Kumar V, Marcus J, Nativ L, Kelly CR. Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for Treatment of Recurrent Clostridioides difficile Infection. J Clin Gastroenterol. 2020 Sep;54(8):701-706. doi: 10.1097/MCG.0000000000001281. PMID: 32011405.
Allegretti JR, Mullish BH. Faecal microbiota transplantations and urinary tract infections - Authors' reply. Lancet. 2020 Jan 25;395(10220):271. doi: 10.1016/S0140-6736(19)32978-2. PMID: 31982069.
Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020 Apr;158(5):1465-1496.e17. doi: 10.1053/j.gastro.2020.01.007. Epub 2020 Jan 13. PMID: 31945351; PMCID: PMC7117094.
Cheng YW, Phelps E, Nemes S, Rogers N, Sagi S, Bohm M, El-Halabi M, Allegretti JR, Kassam Z, Xu H, Fischer M. Fecal Microbiota Transplant Decreases Mortality in Patients with Refractory Severe or Fulminant Clostridioides difficile Infection. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2234-2243.e1. doi: 10.1016/j.cgh.2019.12.029. Epub 2020 Jan 8. PMID: 31923639.
Allegretti JR, Marcus J, Storm M, Sitko J, Kennedy K, Gerber GK, Bry L. Clinical Predictors of Recurrence After Primary Clostridioides difficile Infection: A Prospective Cohort Study. Dig Dis Sci. 2020 Jun;65(6):1761-1766. doi: 10.1007/s10620-019-05900-3. Epub 2019 Oct 30. PMID: 31667694; PMCID: PMC8630805.
2019 Publications
Kassam Z, Dubois N, Ramakrishna B, Ling K, Qazi T, Smith M, Kelly CR, Fischer M, Allegretti JR, Budree S, Panchal P, Kelly CP, Osman M. Donor Screening for Fecal Microbiota Transplantation. N Engl J Med. 2019 Nov 21;381(21):2070-2072. doi: 10.1056/NEJMc1913670. Epub 2019 Oct 30. PMID: 31665572.
Hathorn K, Qazi T, Caton MT, Allegretti JR. Cryptogenic Multifocal Ulcerative Sclerosing Enteritis: A Curious Case of Intestinal Obstruction in the Setting of Human Immunodeficiency Virus. ACG Case Rep J. 2019 May 14;6(5):e00070. doi: 10.14309/crj.0000000000000070. PMID: 31616747; PMCID: PMC6658071.
Elangovan A, Allegretti JR, Fischer M. Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation. Expert Opin Biol Ther. 2019 Dec;19(12):1343-1355. doi: 10.1080/14712598.2019.1673725. Epub 2019 Oct 13. PMID: 31570017.
Cammarota G, Ianiro G, Kelly CR, Mullish BH, Allegretti JR, Kassam Z, Putignani L, Fischer M, Keller JJ, Costello SP, Sokol H, Kump P, Satokari R, Kahn SA, Kao D, Arkkila P, Kuijper EJ, Vehreschild MJG, Pintus C, Lopetuso L, Masucci L, Scaldaferri F, Terveer EM, Nieuwdorp M, López-Sanromán A, Kupcinskas J, Hart A, Tilg H, Gasbarrini A. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut. 2019 Dec;68(12):2111-2121. doi: 10.1136/gutjnl-2019-319548. Epub 2019 Sep 28. PMID: 31563878; PMCID: PMC6872442.
Allegretti JR, Mullish BH, Kelly C, Fischer M. The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications. Lancet. 2019 Aug 3;394(10196):420-431. doi: 10.1016/S0140-6736(19)31266-8. PMID: 31379333.
Allegretti JR, Kassam Z. Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: The Next Steps in This Promising Story. Am J Gastroenterol. 2019 Aug;114(8):1354-1355. doi: 10.14309/ajg.0000000000000317. PMID: 31306151.
Allegretti JR, Kassam Z, Mullish BH, Chiang A, Carrellas M, Hurtado J, Marchesi JR, McDonald JAK, Pechlivanis A, Barker GF, Miguéns Blanco J, Garcia-Perez I, Wong WF, Gerardin Y, Silverstein M, Kennedy K, Thompson C. Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. Clin Gastroenterol Hepatol. 2020 Apr;18(4):855-863.e2. doi: 10.1016/j.cgh.2019.07.006. Epub 2019 Jul 10. PMID: 31301451.
Kelly CR, Fischer M, Grinspan A, Allegretti JR. Patients Eligible for Trials of Microbe-Based Therapeutics Do Not Represent the Population With Recurrent Clostridioides difficile Infection. Clin Gastroenterol Hepatol. 2020 May;18(5):1099-1101. doi: 10.1016/j.cgh.2019.06.034. Epub 2019 Jun 27. PMID: 31254675.
McSweeney B, Allegretti JR, Fischer M, Xu H, Goodman KJ, Monaghan T, McLeod C, Mullish BH, Petrof EO, Phelps EL, Chis R, Edmison A, Juby A, Ennis-Davis R, Roach B, Wong K, Kao D. In search of stool donors: a multicenter study of prior knowledge, perceptions, motivators, and deterrents among potential donors for fecal microbiota transplantation. Gut Microbes. 2020;11(1):51-62. doi: 10.1080/19490976.2019.1611153. Epub 2019 May 23. PMID: 31122134; PMCID: PMC6973337.
Levy AN, Allegretti JR. Insights into the role of fecal microbiota transplantation for the treatment of inflammatory bowel disease. Therap Adv Gastroenterol. 2019 Mar 14;12:1756284819836893. doi: 10.1177/1756284819836893. PMID: 30906424; PMCID: PMC6421596.
Allegretti JR, Kassam Z, Fischer M, Kelly C, Chan WW. Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT). J Clin Gastroenterol. 2019 Oct;53(9):e405-e408. doi: 10.1097/MCG.0000000000001194. PMID: 30882536.
Mullish BH, McDonald JAK, Pechlivanis A, Allegretti JR, Kao D, Barker GF, Kapila D, Petrof EO, Joyce SA, Gahan CGM, Glegola-Madejska I, Williams HRT, Holmes E, Clarke TB, Thursz MR, Marchesi JR. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection. Gut. 2019 Oct;68(10):1791-1800. doi: 10.1136/gutjnl-2018-317842. Epub 2019 Feb 11. PMID: 30816855; PMCID: PMC6839797.
Allegretti JR, Kassam Z, Carrellas M, Mullish BH, Marchesi JR, Pechlivanis A, Smith M, Gerardin Y, Timberlake S, Pratt DS, Korzenik JR. Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial. Am J Gastroenterol. 2019 Jul;114(7):1071-1079. doi: 10.14309/ajg.0000000000000115. PMID: 30730351.
Allegretti JR, Kao D, Phelps E, Roach B, Smith J, Ganapini VC, Kassam Z, Xu H, Fischer M. Risk of Clostridium difficile Infection with Systemic Antimicrobial Therapy Following Successful Fecal Microbiota Transplant: Should We Recommend Anti-Clostridium difficile Antibiotic Prophylaxis? Dig Dis Sci. 2019 Jun;64(6):1668-1671. doi: 10.1007/s10620-018-5450-4. Epub 2019 Jan 10. PMID: 30632052.
Allegretti JR, Fischer M, Sagi SV, Bohm ME, Fadda HM, Ranmal SR, Budree S, Basit AW, Glettig DL, de la Serna EL, Gentile A, Gerardin Y, Timberlake S, Sadovsky R, Smith M, Kassam Z. Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Lose Dose. Dig Dis Sci. 2019 Jun;64(6):1672-1678. doi: 10.1007/s10620-018-5396-6. Epub 2018 Dec 5. Erratum in: Dig Dis Sci. 2019 Feb 18;: PMID: 30519847.
Krajicek E, Fischer M, Allegretti JR, Kelly CR. Nuts and Bolts of Fecal Microbiota Transplantation. Clin Gastroenterol Hepatol. 2019 Jan;17(2):345-352. doi: 10.1016/j.cgh.2018.09.029. Epub 2018 Sep 27. PMID: 30268564.
Cheng YW, Phelps E, Ganapini V, Khan N, Ouyang F, Xu H, Khanna S, Tariq R, Friedman-Moraco RJ, Woodworth MH, Dhere T, Kraft CS, Kao D, Smith J, Le L, El-Nachef N, Kaur N, Kowsika S, Ehrlich A, Smith M, Safdar N, Misch EA, Allegretti JR, Flynn A, Kassam Z, Sharfuddin A, Vuppalanchi R, Fischer M. Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience. Am J Transplant. 2019 Feb;19(2):501-511. doi: 10.1111/ajt.15058. Epub 2018 Aug 31. PMID: 30085388; PMCID: PMC6349556.
2018 Publications
Kearney SM, Gibbons SM, Poyet M, Gurry T, Bullock K, Allegretti JR, Clish CB, Alm EJ. Endospores and other lysis-resistant bacteria comprise a widely shared core community within the human microbiota. ISME J. 2018 Oct;12(10):2403-2416. doi: 10.1038/s41396-018-0192-z. Epub 2018 Jun 13. PMID: 29899513; PMCID: PMC6157131.
Merker AM, Riaz M, Friedman S, Allegretti JR, Korzenik J. Legalization of Medicinal Marijuana Has Minimal Impact on Use Patterns in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Oct 12;24(11):2309-2314. doi: 10.1093/ibd/izy141. PMID: 29788102.
Panchal P, Budree S, Scheeler A, Medina G, Seng M, Wong WF, Elliott R, Eliott R, Mitchell T, Kassam Z, Allegretti JR, Osman M. Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future. Curr Gastroenterol Rep. 2018 Mar 28;20(4):14. doi: 10.1007/s11894-018-0619-8. Erratum in: Curr Gastroenterol Rep. 2018 Jun 8;20(7):28. Eliott R [corrected to Elliott R]. PMID: 29594746.
Smillie CS, Sauk J, Gevers D, Friedman J, Sung J, Youngster I, Hohmann EL, Staley C, Khoruts A, Sadowsky MJ, Allegretti JR, Smith MB, Xavier RJ, Alm EJ. Strain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation. Cell Host Microbe. 2018 Feb 14;23(2):229-240.e5. doi: 10.1016/j.chom.2018.01.003. PMID: 29447696; PMCID: PMC8318347.
Fischer M, Kao D, Kassam Z, Smith J, Louie T, Sipe B, Torbeck M, Xu H, Ouyang F, Mozaffarian D, Allegretti JR. Stool Donor Body Mass Index Does Not Affect Recipient Weight After a Single Fecal Microbiota Transplantation for Clostridium difficile Infection. Clin Gastroenterol Hepatol. 2018 Aug;16(8):1351-1353. doi: 10.1016/j.cgh.2017.12.007. Epub 2017 Dec 12. PMID: 29246701.
Allegretti JR, Kassam Z, Chan WW. Small Intestinal Bacterial Overgrowth: Should Screening Be Included in the Pre-fecal Microbiota Transplantation Evaluation? Dig Dis Sci. 2018 Jan;63(1):193-197. doi: 10.1007/s10620-017-4864-8. Epub 2017 Nov 29. PMID: 29188472; PMCID: PMC6139025.
Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool assessment. Clin Microbiol Infect. 2018 Jul;24(7):780.e1-780.e3. doi: 10.1016/j.cmi.2017.10.022. Epub 2017 Nov 11. PMID: 29104169; PMCID: PMC6156785.
Allegretti JR, Allegretti AS, Phelps E, Xu H, Fischer M, Kassam Z. Classifying Fecal Microbiota Transplantation Failure: An Observational Study Examining Timing and Characteristics of Fecal Microbiota Transplantation Failures. Clin Gastroenterol Hepatol. 2018 Nov;16(11):1832-1833. doi: 10.1016/j.cgh.2017.10.031. Epub 2017 Nov 16. PMID: 29104129.
Allegretti JR, Kao D, Sitko J, Fischer M, Kassam Z. Early Antibiotic Use After Fecal Microbiota Transplantation Increases Risk of Treatment Failure. Clin Infect Dis. 2018 Jan 6;66(1):134-135. doi: 10.1093/cid/cix684. PMID: 29020157.
2017 Publications
Kelly CR, Allegretti JR. FMT in IBD: What Have We Learned? Dig Dis Sci. 2017 Oct;62(10):2618-2620. doi: 10.1007/s10620-017-4713-9. PMID: 28840580.
Razik R, Osman M, Lieberman A, Allegretti JR, Kassam Z. Faecal microbiota transplantation for Clostridium difficile infection: a multicentre study of non-responders. Med J Aust. 2017 Aug 21;207(4):159-160. doi: 10.5694/mja16.01452. PMID: 28814217.
Qazi T, Amaratunga T, Barnes EL, Fischer M, Kassam Z, Allegretti JR. The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis. Gut Microbes. 2017 Nov 2;8(6):574-588. doi: 10.1080/19490976.2017.1353848. Epub 2017 Sep 12. PMID: 28723262; PMCID: PMC5730391.
Allegretti JR, Kassam Z, Osman M, Budree S, Fischer M, Kelly CR. The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection. Gastrointest Endosc. 2018 Jan;87(1):18-29. doi: 10.1016/j.gie.2017.05.036. Epub 2017 Jun 3. PMID: 28583769.
Allegretti JR, Barnes EL, Stevens B, Storm M, Ananthakrishnan A, Yajnik V, Korzenik J. Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. Dig Dis Sci. 2017 Jun;62(6):1590-1596. doi: 10.1007/s10620-017-4549-3. Epub 2017 Mar 29. PMID: 28357697; PMCID: PMC5661939.
2016 Publications
Fischer M, Kao D, Kelly C, Kuchipudi A, Jafri SM, Blumenkehl M, Rex D, Mellow M, Kaur N, Sokol H, Cook G, Hamilton MJ, Phelps E, Sipe B, Xu H, Allegretti JR. Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Oct;22(10):2402-9. doi: 10.1097/MIB.0000000000000908. PMID: 27580384.
Vaughn BP, Vatanen T, Allegretti JR, Bai A, Xavier RJ, Korzenik J, Gevers D, Ting A, Robson SC, Moss AC. Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease. Inflamm Bowel Dis. 2016 Sep;22(9):2182-90. doi: 10.1097/MIB.0000000000000893. PMID: 27542133; PMCID: PMC4995064.
Allegretti JR, Kearney S, Li N, Bogart E, Bullock K, Gerber GK, Bry L, Clish CB, Alm E, Korzenik JR. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment Pharmacol Ther. 2016 Jun;43(11):1142-53. doi: 10.1111/apt.13616. Epub 2016 Apr 18. PMID: 27086647; PMCID: PMC5214573.
Barnes EL, Allegretti JR. Are Anti-Tumor Necrosis Factor Trough Levels Predictive of Mucosal Healing in Patients With Inflammatory Bowel Disease?: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2016 Oct;50(9):733-41. doi: 10.1097/MCG.0000000000000441. PMID: 26535480.
2015 Publications
Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD, Sauk J, Giallourakis C, Garber J, Hamilton MJ, Tomczak M, Makrauer F, Burakoff RB, Levine J, de Silva P, Friedman S, Ananthakrishnan A, Korzenik JR, Yajnik V. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis. 2015 Dec;21(12):2879-85. doi: 10.1097/MIB.0000000000000561. PMID: 26288002; PMCID: PMC4745906.
Allegretti JR, Borges L, Lucci M, Chang M, Cao B, Collins E, Vogel B, Arthur E, Emmons D, Korzenik JR. Risk Factors for Rehospitalization Within 90 Days in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015 Nov;21(11):2583-9. doi: 10.1097/MIB.0000000000000537. PMID: 26244647; PMCID: PMC5189985.
Allegretti JR, Barnes EL, Cameron A. Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis. Inflamm Bowel Dis. 2015 May;21(5):1089-97. doi: 10.1097/MIB.0000000000000338. PMID: 25895005; PMCID: PMC4458370.
2014 Publications
Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection. J Vis Exp. 2014 Dec 8;(94):52154. doi: 10.3791/52154. PMID: 25549239; PMCID: PMC4396937.
Allegretti JR, Hamilton MJ. Restoring the gut microbiome for the treatment of inflammatory bowel diseases. World J Gastroenterol. 2014 Apr 7;20(13):3468-74. doi: 10.3748/wjg.v20.i13.3468. PMID: 24707129; PMCID: PMC3974513.